Thu, Apr 17, 2014, 12:17 PM EDT - U.S. Markets close in 3 hrs 43 mins

Recent

% | $
Quotes you view appear here for quick access.

Pfizer Inc. Message Board

richheide61 12 posts  |  Last Activity: 13 hours ago Member since: Oct 6, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • GET OUT NOW. JOSHUA WILL GO TO JAIL FOR THIS!

  • richheide61 richheide61 Apr 11, 2014 7:54 PM Flag

    Easy Freddie, I don't have any cash at the moment, my wife has breast cancer and I we have many medical bills to pay.
    I was just having some fun.

  • Reply to

    NEWL WILL ROCKET UP HUGE ON MONDAY!

    by richheide61 Apr 11, 2014 7:30 PM
    richheide61 richheide61 Apr 11, 2014 7:44 PM Flag

    Yes Freddie, you can have all my NEWL shares!

  • richheide61 richheide61 Apr 11, 2014 7:39 PM Flag

    no bs here, it will fly past $1 on Monday.
    Post this if It does not, I will eat crow.

    Sentiment: Strong Buy

  • Not

    Sentiment: Strong Buy

  • I guarantee it. Hanover has been naked shorting this the whole time.
    now they want to make even more money by climbing it back up.

    Sentiment: Strong Buy

  • Reply to

    Sold mine yesterday, lost over $9,000

    by tsalogan Apr 11, 2014 4:38 PM
    richheide61 richheide61 Apr 11, 2014 4:56 PM Flag

    TO DATE, I HAVE LOST OVER $197,000 ON THIS ON, BUT I MADE OVER $12 MILLION
    ON PLUG!
    SO I MORE THAN OK WITH THIS LOSS.

  • Reply to

    HOW HIGH NEXT WEEK?? Just bought in...

    by mj.lee2000 Apr 11, 2014 4:33 PM
    richheide61 richheide61 Apr 11, 2014 4:43 PM Flag

    mj, it will go over $1.00 for sure as earnings will post great profit!
    What's your take?

    Sentiment: Strong Buy

  • Reply to

    earning release 4/10/14 for 4th quarter 2013

    by wildbilly2 Mar 25, 2014 8:53 PM
    richheide61 richheide61 Mar 25, 2014 9:25 PM Flag

    It will hit over $4 IMHO

    Sentiment: Strong Buy

  • Pharmaceutical Giant to Acquire Israeli Stem Cell Developer for $600 Million
    Novartis and Gamida-Cell Ltd. are currently engaged in talks over a potential acquisition

    By: Daniel Koren
    Published: March 19th, 2014 in Business » Israel

    submit to reddit digg Pharmaceutical Giant to Acquire Israeli Stem Cell Developer for $600 Million
    Novartis International AG, the Swiss multinational pharmaceutical giant, is reportedly in talks to acquire Israeli-based stem cell developer, Gamida-Cell Ltd., reports Globes.

    The acquisition will cost Novartis upwards of approximately $600 million.

    Novartis' interest in Gamida-Cell has to do with the company's proprietary technology, allowing them to grow the number and density of stem cells within certain blood samples, which eventually increases stem cell activity.

    Gamida-Cell has thus far been looking to cure blood cancer in adults, work that Novartis will continue following its acquisition.

    The Israeli company released its first product in conjunction with Teva, Israel's preeminent and largest pharmaceutical company; however, due to changes in the U.S. Food and Drug Administration, Gamida and Teva were unable to finish developing the product because of financial restraints.

    Gamida-Cell is currently developing a new product undergoing clinical trials without the assistance of Teva, which makes the sale to Novartis possible, says Globes. They add that 53% of the Gamida-Cell is owned by two companies: Elbit Medical Technologies Ltd. owning 31%, and Clal Biotechnology Industries Ltd. owning 22%.

    Before conducting talks with Navartis, Gamida-Cell was potentially seeking an IPO in the U.S., but the newly discussed deal will see high profits for the owners, and will hopefully bring their latest product that much closer to the market.

    Startup Club: magicJack
    Startup Club: magicJack
    TrendingFirst Rolls-Royce Rolls Into Israel [VIDEO]
    First Rolls-Royce Rolls Into Israel [VIDEO]
    TrendingAll Dolled Up and Everywhere to Go
    All Dolled Up and Everywhere to Go
    Trending
    Facebook Likes
    18828
    Fans
    Twitter Followers
    10250
    Followers
    RSS
    24,687
    Subscribers
    OUR FACEBOOK FANS


    JEWISH TWEETS

    submit
    Pharmaceutical Giant to Acquire Israeli Stem Cell Developer for $600 Million
    Novartis and Gamida-Cell Ltd. are currently engaged in talks over a potential acquisition

    By: Daniel Koren
    Published: March 19th, 2014 in Business » Israel

    submit to reddit digg Pharmaceutical Giant to Acquire Israeli Stem Cell Developer for $600 Million
    Novartis International AG, the Swiss multinational pharmaceutical giant, is reportedly in talks to acquire Israeli-based stem cell developer, Gamida-Cell Ltd., reports Globes.

    The acquisition will cost Novartis upwards of approximately $600 million.

    Novartis' interest in Gamida-Cell has to do with the company's proprietary technology, allowing them to grow the number and density of stem cells within certain blood samples, which eventually increases stem cell activity.

    Gamida-Cell has thus far been looking to cure blood cancer in adults, work that Novartis will continue following its acquisition.

    The Israeli company released its first product in conjunction with Teva, Israel's preeminent and largest pharmaceutical company; however, due to changes in the U.S. Food and Drug Administration, Gamida and Teva were unable to finish developing the product because of financial restraints.

    Gamida-Cell is currently developing a new product undergoing clinical trials without the assistance of Teva, which makes the sale to Novartis possible, says Globes. They add that 53% of the Gamida-Cell is owned by two companies: Elbit Medical Technologies Ltd. owning 31%, and Clal Biotechnology Industries Ltd. owning 22%.

    Before conducting talks with Navartis, Gamida-Cell was potentially seeking an IPO in the U.S., but the newly discussed deal will see high profits for the owners, and will hopefully bring their latest product that much closer to the market.

    Startup Club: magicJack
    Startup Club: magicJack
    TrendingFirst Rolls-Royce Rolls Into Israel [VIDEO]
    First Rolls-Royce Rolls Into Israel [VIDEO]
    TrendingAll Dolled Up and Everywhere to Go
    All Dolled Up and Everywhere to Go
    Trending
    Facebook Likes
    18828
    Fans
    Twitter Followers
    10250
    Followers
    RSS
    24,687
    Subscribers
    OUR FACEBOOK FANS


    JEWISH TWEETS

    submit

    Pharmaceutical Giant to Acquire Israeli Stem Cell Developer for $600 Million
    Novartis and Gamida-Cell Ltd. are currently engaged in talks over a potential acquisition

    By: Daniel Koren
    Published: March 19th, 2014 in Business » Israel

    submit to reddit digg Pharmaceutical Giant to Acquire Israeli Stem Cell Developer for $600 Million
    Novartis International AG, the Swiss multinational pharmaceutical giant, is reportedly in talks to acquire Israeli-based stem cell developer, Gamida-Cell Ltd., reports Globes.

    The acquisition will cost Novartis upwards of approximately $600 million.

    Novartis' interest in Gamida-Cell has to do with the company's proprietary technology, allowing them to grow the number and density of stem cells within certain blood samples, which eventually increases stem cell activity.

    Gamida-Cell has thus far been looking to cure blood cancer in adults, work that Novartis will continue following its acquisition.

    The Israeli company released its first product in conjunction with Teva, Israel's preeminent and largest pharmaceutical company; however, due to changes in the U.S. Food and Drug Administration, Gamida and Teva were unable to finish developing the product because of financial restraints.

    Gamida-Cell is currently developing a new product undergoing clinical trials without the assistance of Teva, which makes the sale to Novartis possible, says Globes. They add that 53% of the Gamida-Cell is owned by two companies: Elbit Medical Technologies Ltd. owning 31%, and Clal Biotechnology Industries Ltd. owning 22%.

    Before conducting talks with Navartis, Gamida-Cell was potentially seeking an IPO in the U.S., but the newly discussed deal will see high profits for the owners, and will hopefully bring their latest product that much closer to the market.

    Startup Club: magicJack
    Startup Club: magicJack
    TrendingFirst Rolls-Royce Rolls Into Israel [VIDEO]
    First Rolls-Royce Rolls Into Israel [VIDEO]
    TrendingAll Dolled Up and Everywhere to Go
    All Dolled Up and Everywhere to Go
    Trending
    Facebook Likes
    18828
    Fans
    Twitter Followers
    10250
    Followers
    RSS
    24,687
    Subscribers
    OUR FACEBOOK FANS


    JEWISH TWEETS

    submit

    Novartis International AG, the Swiss multinational pharmaceutical giant, is reportedly in talks to acquire Israeli-based stem cell developer, Gamida-Cell Ltd., reports Globes.

    The acquisition will cost Novartis upwards of approximately $600 million.

    Novartis' interest in Gamida-Cell has to do with the company's proprietary technology, allowing them to grow the number and density of stem cells within certain blood samples, which eventually increases stem cell activity.

    Gamida-Cell has thus far been looking to cure blood cancer in adults, work that Novartis will continue following its acquisition.

    The Israeli company released its first product in conjunction with Teva, Israel's preeminent and largest pharmaceutical company; however, due to changes in the U.S. Food and Drug Administration, Gamida and Teva were unable to finish developing the product because of financial restraints.

    Gamida-Cell is currently developing a new product undergoing clinical trials without the assistance of Teva, which makes the sale to Novartis possible, says Globes. They add that 53% of the Gamida-Cell is owned by two companies: Elbit Medical Technologies Ltd. owning 31%, and Clal Biotechnology Industries Ltd. owning 22%.

    Before conducting talks with Navartis, Gamida-Cell was potentially seeking an IPO in the U.S., but the newly discussed deal will see high profits for the owners, and will hopefully bring their latest product that much closer to the market.

    Startup Club: magicJack
    Startup Club: magicJack
    TrendingFirst Rolls-Royce Rolls Into Israel [VIDEO]
    First Rolls-Royce Rolls Into Israel [VIDEO]
    TrendingAll Dolled Up and Everywhere to Go
    All Dolled Up and Everywhere to Go
    Trending
    Facebook Likes
    18828
    Fans
    Twitter Followers
    10250
    Followers
    RSS
    24,687
    Subscribers
    OUR FACEBOOK FANS


    JEWISH TWEETS

    submit

    Novartis International AG, the Swiss multinational pharmaceutical giant, is reportedly in talks to acquire Israeli-based stem cell developer, Gamida-Cell Ltd., reports Globes.

    The acquisition will cost Novartis upwards of approximately $600 million.

    Novartis' interest in Gamida-Cell has to do with the company's proprietary technology, allowing them to grow the number and density of stem cells within certain blood samples, which eventually increases stem cell activity.

    Gamida-Cell has thus far been looking to cure blood cancer in adults, work that Novartis will continue following its acquisition.

    The Israeli company released its first product in conjunction with Teva, Israel's preeminent and largest pharmaceutical company; however, due to changes in the U.S. Food and Drug Administration, Gamida and Teva were unable to finish developing the product because of financial restraints.

    Gamida-Cell is currently developing a new product undergoing clinical trials without the assistance of Teva, which makes the sale to Novartis possible, says Globes. They add that 53% of the Gamida-Cell is owned by two companies: Elbit Medical Technologies Ltd. owning 31%, and Clal Biotechnology Industries Ltd. owning 22%.

    Before conducting talks with Navartis, Gamida-Cell was potentially seeking an IPO in the U.S., but the newly discussed deal will see high profits for the owners, and will hopefully bring their latest product that much closer to the market.

    Startup Club: magicJack
    Startup Club: magicJack
    TrendingFirst Rolls-Royce Rolls Into Israel [VIDEO]
    First Rolls-Royce Rolls Into Israel [VIDEO]
    TrendingAll Dolled Up and Everywhere to Go
    All Dolled Up and Everywhere to Go
    Trending
    Facebook Likes
    18828
    Fans
    Twitter Followers
    10250
    Followers
    RSS
    24,687
    Subscribers
    OUR FACEBOOK FANS


    JEWISH TWEETS

    submit

    Novartis International AG, the Swiss multinational pharmaceutical giant, is reportedly in talks to acquire Israeli-based stem cell developer, Gamida-Cell Ltd., reports Globes.

    The acquisition will cost Novartis upwards of approximately $600 million.

    Novartis' interest in Gamida-Cell has to do with the company's proprietary technology, allowing them to grow the number and density of stem cells within certain blood samples, which eventually increases stem cell activity.

    Gamida-Cell has thus far been looking to cure blood cancer in adults, work that Novartis will continue following its acquisition.

    The Israeli company released its first product in conjunction with Teva, Israel's preeminent and largest pharmaceutical company; however, due to changes in the U.S. Food and Drug Administration, Gamida and Teva were unable to finish developing the product because of financial restraints.

    Gamida-Cell is currently developing a new product undergoing clinical trials without the assistance of Teva, which makes the sale to Novartis possible, says Globes. They add that 53% of the Gamida-Cell is owned by two companies: Elbit Medical Technologies Ltd. owning 31%, and Clal Biotechnology Industries Ltd. owning 22%.

    Before conducting talks with Navartis, Gamida-Cell was potentially seeking an IPO in the U.S., but the newly discussed deal will see high profits for the owners, and will hopefully bring their latest product that much closer to the market.

    Startup Club: magicJack
    Startup Club: magicJack
    TrendingFirst Rolls-Royce Rolls Into Israel [VIDEO]
    First Rolls-Royce Rolls Into Israel [VIDEO]
    TrendingAll Dolled Up and Everywhere to Go
    All Dolled Up and Everywhere to Go
    Trending
    Facebook Likes
    18828
    Fans
    Twitter Followers
    10250
    Followers
    RSS
    24,687
    Subscribers
    OUR FACEBOOK FANS


    JEWISH TWEETS

    submit

    Novartis International AG, the Swiss multinational pharmaceutical giant, is reportedly in talks to acquire Israeli-based stem cell developer, Gamida-Cell Ltd., reports Globes.

    The acquisition will cost Novartis upwards of approximately $600 million.

    Novartis' interest in Gamida-Cell has to do with the company's proprietary technology, allowing them to grow the number and density of stem cells within certain blood samples, which eventually increases stem cell activity.

    Gamida-Cell has thus far been looking to cure blood cancer in adults, work that Novartis will continue following its acquisition.

    The Israeli company released its first product in conjunction with Teva, Israel's preeminent and largest pharmaceutical company; however, due to changes in the U.S. Food and Drug Administration, Gamida and Teva were unable to finish developing the product because of financial restraints.

    Gamida-Cell is currently developing a new product undergoing clinical trials without the assistance of Teva, which makes the sale to Novartis possible, says Globes. They add that 53% of the Gamida-Cell is owned by two companies: Elbit Medical Technologies Ltd. owning 31%, and Clal Biotechnology Industries Ltd. owning 22%.

    Before conducting talks with Navartis, Gamida-Cell was potentially seeking an IPO in the U.S., but the newly discussed deal will see high profits for the owners, and will hopefully bring their latest product that much closer to the market.

    Startup Club: magicJack
    Startup Club: magicJack
    TrendingFirst Rolls-Royce Rolls Into Israel [VIDEO]
    First Rolls-Royce Rolls Into Israel [VIDEO]
    TrendingAll Dolled Up and Everywhere to Go
    All Dolled Up and Everywhere to Go
    Trending
    Facebook Likes
    18828
    Fans
    Twitter Followers
    10250
    Followers
    RSS
    24,687
    Subscribers
    OUR FACEBOOK FANS


    JEWISH TWEETS

    submit

    ovartis International AG, the Swiss multinational pharmaceutical giant, is reportedly in talks to acquire Israeli-based stem cell developer, Gamida-Cell Ltd., reports Globes.

    The acquisition will cost Novartis upwards of approximately $600 million.

    Novartis' interest in Gamida-Cell has to do with the company's proprietary technology, allowing them to grow the number and density of stem cells within certain blood samples, which eventually increases stem cell activity.

    Gamida-Cell has thus far been looking to cure blood cancer in adults, work that Novartis will continue following its acquisition.

    The Israeli company released its first product in conjunction with Teva, Israel's preeminent and largest pharmaceutical company; however, due to changes in the U.S. Food and Drug Administration, Gamida and Teva were unable to finish developing the product because of financial restraints.

    Gamida-Cell is currently developing a new product undergoing clinical trials without the assistance of Teva, which makes the sale to Novartis possible, says Globes. They add that 53% of the Gamida-Cell is owned by two companies: Elbit Medical Technologies Ltd. owning 31%, and Clal Biotechnology Industries Ltd. owning 22%.

    Before conducting talks with Navartis, Gamida-Cell was potentially seeking an IPO in the U.S., but the newly discussed deal will see high profits for the owners, and will hopefully bring their latest product that much closer to the market.

    Startup Club: magicJack
    Startup Club: magicJack
    TrendingFirst Rolls-Royce Rolls Into Israel [VIDEO]
    First Rolls-Royce Rolls Into Israel [VIDEO]
    TrendingAll Dolled Up and Everywhere to Go
    All Dolled Up and Everywhere to Go
    Trending
    Facebook Likes
    18828
    Fans
    Twitter Followers
    10250
    Followers
    RSS
    24,687
    Subscribers
    OUR FACEBOOK FANS


    JEWISH TWEETS

    submit

    Novartis International AG, the Swiss multinational pharmaceutical giant, is reportedly in talks to acquire Israeli-based stem cell developer, Gamida-Cell Ltd., reports Globes.

    The acquisition will cost Novartis upwards of approximately $600 million.

    Novartis' interest in Gamida-Cell has to do with the company's proprietary technology, allowing them to grow the number and density of stem cells within certain blood samples, which eventually increases stem cell activity.

    Gamida-Cell has thus far been looking to cure blood cancer in adults, work that Novartis will continue following its acquisition.

    The Israeli company released its first product in conjunction with Teva, Israel's preeminent and largest pharmaceutical company; however, due to changes in the U.S. Food and Drug Administration, Gamida and Teva were unable to finish developing the product because of financial restraints.

    Gamida-Cell is currently developing a new product undergoing clinical trials without the assistance of Teva, which makes the sale to Novartis possible, says Globes. They add that 53% of the Gamida-Cell is owned by two companies: Elbit Medical Technologies Ltd. owning 31%, and Clal Biotechnology Industries Ltd. owning 22%.

    Before conducting talks with Navartis, Gamida-Cell was potentially seeking an IPO in the U.S., but the newly discussed deal will see high profits for the owners, and will hopefully bring their latest product that much closer to the market.

  • http://www.shalomlife.com/business/22422/pharmaceutical-giant-to-acquire-israeli-stem-cell-developer-for-600-million/

  • Reply to

    PUMP AND DUMP. see u at $3 soon

    by blcktower Mar 2, 2014 4:26 PM
    richheide61 richheide61 Mar 2, 2014 5:41 PM Flag

    You Wish. not gonna happen.

    Too much going for it!

    Sentiment: Strong Buy

PFE
30.23+0.1400(+0.47%)12:16 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.